CA2893333C — Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds

USPTO Abstract

Described herein are compounds of formula l, (see formula I) wherein the variables R1, R2, R5 and b are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. For example, the pharmaceutical composition described herein can be administered in a therapeutically effective amount to a mammal, including a human, in need thereof for: inhibiting BACE1 and/or BACE2 activity for the therapeutic and/or prophylactic treatment of diseases and disorders characterized by elevated .beta.-amyloid levels, including diabetes or type 2 diabtetes; treating neurodegenerative disease and, in particular, Alzheimer's Disease; inihibting production of amyloid-.beta. protein and for inhibiting beta-site amyloid precursor protein cleaving enzyme 1 (BACE1); and increasing insulin sensitivity in skeletal muscle and liver in a mammal.